RecallRadar

FDA Drug recall D-0210-2025

Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US…

On 2025-02-05 the FDA classified a Class I recall of Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US… by Astellas Pharma Us, citing failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0210-2025
ClassificationClass I
Statusongoing
Initiated2024-12-23
Published2025-02-05
Last updated2026-09-13 11:52 UTC
CompanyAstellas Pharma Us
DistributionUS

Product

Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US Inc., Northbrook, IL 60062, NDC 0469-0647-73.

Reason

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Identifiers

ndc0469-0647-73
ndc0469-0647-11
ndc0469-0677-73
ndc0469-0677-11
ndc0469-0687-73
ndc0469-0687-11
code_infoLot# 0R3092A, EXP 03/31/2026

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0210-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.